BRISTOL-MYERS BUFFERIN STUDIES SUPPORT OTC CLAIM OF REDUCED STOMACH DISTRESS WHEN USED SHORT-TERM, FDA SAYS; CHRONIC USE CLAIM NEEDS FURTHER DATA